Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares second interim results that include 100% protection against serious diseases, including hospitalization
British biotech firm’s 750 mn GM mosquitoes will mate with females outside Florida and sow a deadly gene
Global Medicine of Prostate Cancer Surgery 2021 Opportunities, Challenges, Key Actors, Predisposition to 2031 | AstraZeneca plc, Active Biotech, Bristol Myers-Squibb
Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares Phase 3 COVAXIN interim results, shows 81% efficiency Nasdaq: OCGN
Ocugen’s COVID-19 co-vaccine development partner, Bharat Biotech, shares Phase 3 COVAXIN Interim Results, Shows 81% Efficiency